Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide / 한국유방암학회지
Jungsil RO; Fiona-Tsui-Fen CHENG; Virote SRIURANPONG; Antonio VILLALON; B-K SMRUTI; Janice TSANG; Yoon-Sim YAP.
Journal of Breast Cancer
; : 8-17, 2016.
Artículo
en Inglés
| WPRIM | ID: wpr-159291
Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which enrolled mainly Western patients. Eribulin has recently been approved in an increasing number of Asian countries; however, there is limited clinical experience in using the drug in certain countries. Therefore, we established an Asian working group to provide practical guidance for eribulin use based on our clinical experience. This paper summarizes the key clinical trials, and the management recommendations for the reported adverse events (AEs) of eribulin in mBC treatment, with an emphasis on those that are relevant to Asian patients, followed by further elaboration of our eribulin clinical experience. It is anticipated that this clinical practice guide will improve the management of AEs resulting from eribulin treatment, which will ensure that patients receive the maximum treatment benefit.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados